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Introduction
Allergic asthma is now regarded as a T cell–mediated
disorder in which sensitized individuals develop
eosinophilic airway inflammation in response to inhala-
tion of aeroallergen (1). T lymphocytes respond to anti-
gen after it has been presented as immunogenic pep-
tides in the context of MHC molecules. Naive T cells
proliferate and differentiate in response to T-cell recep-
tor (TCR) recognition of peptide-MHC only when
accompanied by costimulatory signals (e.g., CD80 and
CD86) provided on the surface of professional APCs. It
is now clear that the dendritic cell (DC) is the most pow-
erful antigen-presenting cell (APC) for inducing a pri-
mary immune response in vivo. It has potent antigen
capturing and presenting capacity and readily express-
es costimulatory ligands for naive T cells (2). The DC
network within the epithelium of the conducting air-
ways is ideally positioned to perform a surveillance role
for inhaled antigens/allergens, and as the only resident
cell population expressing surface MHC class II in nor-
mal (noninflamed) epithelium, the DCs are likely to
play an important role in primary allergic sensitization
to aeroallergens (3–5). After antigen uptake, airway DCs
migrate to the paracortical T-cell zone of the draining
lymph nodes (LNs) of the lung, where they interact with
naive T cells (6). During this interaction with naive T
cells, the DC becomes a reporter of its earlier microen-
vironment and has the potential to induce a polarized
Th1 or Th2 type of response (7). The determining fac-
tors by which DCs will induce either a Th1 or a Th2 type
of response are multiple and relate to the type of DC
presenting the antigen (Ag) (8, 9), their capacity to pro-
duce polarizing cytokines such as IL-12 and IL-6 (10),
the maturity of the DC network (11), the degree and
type of costimulation provided to T cells (12), and the
presence of inflammation during Ag encounter (11).
Despite the critical role that DCs might play in the
polarization of Th responses in the airways, few stud-
ies have examined the contribution of DC to Th2-driv-
en sensitization to aeroallergen. The purpose of this
study was to investigate whether and under which con-
ditions injection of Ag-pulsed DCs into the airways
leads to sensitization to inhaled Ag and to the devel-
opment of Ag-induced airway eosinophilia.
Methods
Experimental animals. C57BL/6 mice were purchased
from Harlan (Zeist, The Netherlands) and housed
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under specific pathogen–free conditions in sterile
microisolator units. C57BL/6 mice with a targeted
mutation of the IL-4 gene (IL4tm1Cgn), with a targeted
mutation of the CD28 gene (CD28–/–), and control
wild-type littermates were purchased from The Jackson
Laboratory (Bar Harbor, Maine, USA).
Culture and antigen loading of bone marrow DCs. DCs
were isolated as reported in detail previously (13, 14).
Bone marrow was magnetically depleted of CD4+,
CD8+, MHC class II+, B220+ and Gr-1+ cells. Lineage–
cells were grown in medium supplemented with 10
ng/mL of rhFlt3-ligand, 200 ng/mL rmGM-CSF and 1
· 103 U/mL rmIL-4. For transfer experiments into IL-
4–deficient animals, DCs were grown in the absence of
exogenous IL-4. After 4 days of culture, cells were
placed in serum-free medium (Optimem-1; N.V. Life
Technologies SA, Merelbeke, Belgium). At day 9, non-
adherent cells were collected and enriched by density
centrifugation over metrizamide (14.5% wt/vol; 600 g
for 20 minutes; Sigma Chemical Co., St. Louis, Mis-
souri, USA). After purification, FACS analysis (Becton
Dickinson Immunocytometry Systems, San Jose, Cali-
fornia, USA) revealed that almost all cells coexpressed
MHC class II and the DC marker CD11c; greater than
95% expressed the costimulatory molecules CD86,
HSA, CD44, and ICAM-1, and approximately 50%
expressed CD80 as reported in detail previously (14).
In initial experiments, purified DCs were incubated
for 2 hours with 100 m g/mL of ovalbumin (OVA) (grade
V; Sigma Chemical Co.) or, as a control, with medium
alone, followed by extensive washing to remove free
OVA. In later experiments, the OVA-pulsing period was
performed overnight, leading to enhanced immunos-
timulatory capacity (see later here).
Intratracheal injection of DCs. Mice were anesthetized
(avertin 2.5% wt/vol in PBS), and 80 m L of cell suspen-
sion was injected intratracheally, using the technique
of Ho and Furst (15). To study the distribution of
injected DCs, cells were labeled with the green fluores-
cent dye carboxyfluorescein diacetate succinimidylester
(CFSE; Molecular Probes Inc., Eugene, Oregon, USA),
essentially as described elsewhere (6). A total of 1 · 106
DCs were instilled intratracheally into naive mice and
traced 12 hours, 36 hours, and 120 hours later in the
bronchoalveolar lavage fluid (BALF), lung tissue, and
mediastinal and inguinal LNs. Lungs were first per-
fused via the right ventricle using PBS, followed by BAL
(see later here). Excised tissues were minced, incubated
for 90 minutes in 100 U/mL collagenase IV (N.V. Life
Technologies SA) and 0.02 mg/mL DNaseI (Sigma
Chemical Co.), and CFSE+ CD11c+ DC were enumerat-
ed using flow cytometry.
Immunization with antigen-pulsed DCs and secondary
exposure to antigen aerosol. On day 0, groups of mice (n
= 6–8 per group) were immunized by intratracheal
instillation of either 1 · 106, 1 · 105, or 1 · 104 OVA-
DCs. As a control, a group of mice received 1 · 106
control PBS-DCs. From day 14 to day 20, mice were
exposed either to seven OVA aerosols (10 mg/mL;
grade III in PBS) or seven PBS aerosols, on consecu-
tive days for 30 minutes daily (5).
Treatment with mAb’s. To study the effect on sensiti-
zation of blocking the interaction of T1/ST2 with its
ligand, 50 m g of purified rat mAb 3E10, recognizing
the T1/ST2 molecule on Th2 cells (16) was injected
intratracheally simultaneously with OVA-DCs at day
0. Rat IgG1 was used as a control. In separate experi-
ments, mice received 30 m g of T1/ST2-Ig fusion pro-
tein that directly competes with membrane-bound
T1/ST2 for binding with its putative ligand and hence
blocks T1/ST2 signaling (16). Human Ig (hu-Ig) was
used as control.
BAL. Twenty-four hours after the last aerosol expo-
sure, mice were killed and BAL was performed (5). The
BALF was centrifuged, cells were counted, and super-
natant was stored. Differential cell counts were per-
formed on cytospin preparations stained with May-
Grünwald-Giemsa. Aliquots of 2 · 105 cells were
prepared for flow cytometry.
Flow cytometry. The following antibodies were used
to stain cells obtained from BALF and/or LNs: CD3 e -
PECy5, CD4-FITC, CD8 a -PE, CD25-PE, CD69-PE,
T1/ST2 (3E10, rat IgG1). On bone marrow DC prepa-
rations, we used I-Ab,d-FITC, CD11c-bi, CD80-PE,
CD86-PE, CD44-PE, HSA-PE, ICAM-1-PE, and B-cell
mAb CD45R-PE (B220). Antibodies were obtained
commercially from PharMingen (San Diego, Califor-
nia, USA) or were from American Type Culture Col-
lection (Manassas, Virginia, USA). Biotinylated anti-
bodies were detected using streptavidin-PECy5
(Quantum Red; Sigma Chemical Co.). Unconjugated
rat mAb’s were detected by secondary goat anti-rat
IgG-PE (Jackson Immunoresearch Laboratories, West
Grove, Pennsylvania, USA). Expression of the T1/ST2-
ligand on DC was demonstrated by binding of
T1/ST2-Ig fusion protein, followed by anti-human
IgG1-FITC (16). Samples were analyzed on a FACS-
Vantage flow cytometer using Cell Quest software
(Becton Dickinson Immunocytometry Systems).
For the single-cell detection of intracellular cytokines,
BALF cells were stimulated for 5 hours at 3 · 106
cells/mL in plates coated with anti-CD3 antibody (2
m g/mL of 145-2C11 antibody), in the presence of anti-
CD28 mAb to provide costimulation, or with PMA/ion-
omycin (17). After 2 hours, monensin (2 m M; PharMin-
gen) was added. After washing, cells were incubated
with 2.4G2, followed by surface staining for CD3-
PECy5 and CD4-FITC. Fixation, permeabilization, and
staining for intracellular cytokines was performed using
anti–IFN- g -allophycocyanin (XMG1.2), anti–IL-4-PE
(11B11), and anti–IL-5-allophycocyanin (TRFK-5)
mAb’s, according to PharMingen’s protocol. Samples
were analyzed on a FACScalibur flow cytometer (Becton
Dickinson Immunocytometry Systems).
Cytokine measurements. The cytokine content in
unconcentrated BALF was determined using ELISA
(IFN- g Quantikine M; R&D Systems, Abingdon, Unit-
ed Kingdom; IL-4 from Biotrak, Life Science, Amer-
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sham, United Kingdom). Ex vivo production of
cytokines by lymphocytes taken from mediastinal and
inguinal LNs 24 hours after the last aerosol challenge
was measured after restimulation at 2 · 106 cells/mL in
the presence or absence of 10 m g/mL of OVA, as
described by others previously (18). After 96 hours of
culture, supernatant was assayed for IL-4, IL-5, and
IFN- g content using ELISA (OptiEIA; PharMingen).
Airway histology. After BAL was performed, fixative (4%
paraformaldehyde in PBS) was gently infused through
the lavage catheter under pressure and volume con-
trolled conditions. The resected lungs were fixed for an
additional 4 hours and paraffin embedded. Four-
micrometer sections were stained with hematoxylin
and eosin (H&E; ref. 5).
Measurement of serum OVA-IgE. Blood was drawn by
cardiac puncture for measurement of serum OVA-IgE
by isotype-specific ELISA (5).
Statistical analysis. Comparison of means between
different groups was performed with the Mann-
Whitney U test for unpaired data using the Spread-
ware Statistics (Spreadware, Palm Desert, California,
USA) statistical package. Differences were considered
significant if P < 0.05.
Results
Injected DCs home to the mediastinal LNs. At various time
points after intratracheal injection, we studied the dis-
tribution of CFSE-labeled DCs. By 12 hours after instil-
lation, CFSE+DCs could be detected in BALF (14.10 ±
2.99% of cells), digested lung tissue (0.17 ± 0.04% of
cells), and draining mediastinal LNs (0.012 ± 0.005%).
No CFSE+ DCs could be detected in inguinal LNs. As
shown in Figure 1a, by 36 hours DCs had further
migrated to the mediastinal LNs (0.07 ± 0.01%) and
gradually disappeared from the BALF (5.83 ± 0.88%).
The number and kinetics of DC migrating into the
draining LNs are shown in Figure 1b. Although by 120
hours, a majority of injected cells had disappeared,
some CFSE+ DCs could still be detected in all com-
partments (1.34 ± 0.15% of BAL; 0.04 ± 0.01% for lung;
and 0.016 ± 0.006% for LN).
Effect of aerosol exposure on airway inflammation in ani-
mals immunized with DCs. Analysis on BALF cells
revealed that seven OVA aerosol exposures induced a
significant increase in total cell counts, mononuclear
cells, eosinophils, neutrophils, and lymphocytes in
mice that were immunized with 1 · 106 OVA-DCs,
compared with animals immunized with PBS-DC
(Figure 2a; P < 0.05). Aerosolization with PBS in OVA-
DC–immunized mice did not induce significant
changes in BALF compared with PBS-DC/PBS–
exposed animals or PBS-DC/OVA–exposed animals.
Immunization with 1 · 105 OVA-DC and subsequent
exposure to OVA aerosol induced an increase in BALF
lymphocytes only, whereas immunization with 1 · 104
OVA-DC induced no significant response (data not
shown). All subsequent immunizations were therefore
performed using 1 · 106 cells.
As studied by flow cytometry and shown in Figure 2b,
exposure to OVA aerosol in OVA-DC mice induced a
significant increase in both CD4+ and CD8+ T cells
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Figure 1
(a) Localization of CFSE+ DC 36 hours after intratracheal injection
of 1 · 106 DCs into naive mice. DC were identified in BALF, digested
lung tissue, and mediastinal and inguinal LNs as CD3–B220– cells of
low autofluorescence, strongly expressing CD11c. Injected DCs can
be discriminated from endogenous DCs by green fluorescence of
CFSE. The percentage of CFSE+ DCs among all LN cells is indicated.
(b) Kinetics of appearance of CFSE+ DC in BALF (open squares, left
y axis) and mediastinal LNs (filled squares, right y axis). Representa-
tive of five mice per time point in the group.
Figure 2
Effect of OVA exposure on the cellular composition of BALF in ani-
mals immunized with DCs. On day 0, mice were immunized by intra-
tracheal administration of 1 · 106 OVA-DCs or control PBS-DCs. On
days 14–20, mice were exposed to 30 minutes of daily OVA or PBS
aerosol. At 24 hours after the last aerosol (day 21), BAL was per-
formed. Groups are coded as immunization/aerosol exposure. (a)
Differential cell counts based on Giemsa staining. (b) Total T lym-
phocytes (CD3) and subsets (CD4 and CD8) in BALF as determined
by flow cytometry. Results are expressed as means ± SEM from eight
to ten mice per group. Mono, monocytes; neutro, neutrophils; eosi-
no, eosinophils; lymph, lymphocytes.
compared with PBS exposure. In the absence of sec-
ondary OVA exposure, there was no difference in total
CD3+ T-cells or T-cell subsets in animals immunized
with OVA-DC compared with those immunized with
PBS-DC. The early activation marker CD69 was
expressed on 62.9 ± 3.2% of CD4+ T cells, and the late
activation marker CD25 (IL-2R) was expressed on 34.0
± 3.5% of CD4+ T cells in the OVA-DC/OVA group com-
pared with 11.5 ± 0.9% and 5.4 ± 0.8%, respectively, in
the PBS-DC/PBS group (P < 0.05).
Lung sections from OVA-DC mice exposed to PBS
aerosol (data not shown) or PBS-DC mice exposed to
OVA (Figure 3a) or PBS aerosol demonstrated no
pathological changes. In contrast, histological analysis
of lung tissue from OVA-DC/OVA–exposed mice
revealed intense multifocal eosinophilic lesions local-
ized mainly in the peribronchial submucosa, but also
marked in the perivascular area (Figure 3b). The vascu-
lar wall was grossly edematous, and in some inflamed
blood vessels, eosinophils were seen to adhere to vas-
cular endothelium. Epithelial changes of goblet cell
hyperplasia were readily seen (Figure 3c).
Effect of aerosol exposure on cytokine levels in animals
immunized with DCs. The type of Th response being
induced by DCs was determined. As shown in Figure
4a, OVA exposure in OVA-DC mice induced a specific
twofold increase in the amount of IL-4 detected in
BALF, compared with that detected in PBS-DC/PBS
mice (P < 0.05). There was no difference in the
amount of IFN- g detectable in BALF. Levels of IL-5
were below the detection limit of our assay.
In vitro restimulation of LN cells (Figure 4, b and c)
with OVA demonstrated that mediastinal lymphocytes
from OVA-DC/OVA mice produced 27 times more IL-
4 (747.4 ± 16.9 vs. 27.2 ± 0.1 pg/mL; P < 0.05), 1.8 times
more IL-5 (3,120.2 ± 13.3 vs. 1,698.6 ± 48.6 pg/mL; P <
0.05), and equal amounts of IFN-g (580 ± 63.6 vs. 876.6
± 172 pg/mL; P > 0.05) compared with those from
PBS-DC/PBS mice. In nondraining LNs, levels of all
cytokines were identical between OVA-DC/OVA and
PBS-DC/PBS mice.
To investigate whether OVA exposure in OVA-DC mice
led to selective infiltration of the lungs with lymphocytes
producing either Th1- or Th2-type cytokines, intracel-
lular staining for cytokines was performed on BALF cells
(Figure 5). Data on percentage expression on CD4+ and
CD8+ cells in OVA-DC/OVA and PBS-DC/PBS mice are
summarized in Table 1. Simultaneous staining for IL-5
and IFN-g was not performed in the PBS-DC/PBS group,
due to lower cell yield in this group.
To study the functional role of IL-4 in this model,
DCs were grown from wild-type donors in the absence
of exogenous IL-4, and transferred into IL-4+/+ or IL-4–/–
mice. Aerosolization with OVA after immunization
with OVA-DC induced airway eosinophilia in IL-4+/+
mice (47.7 ± 4.75% of BALF cells) but not in IL-4–/– mice
(0.2 ± 0.14% of cells). It should be noted that in this
experiment, the percentage of BALF eosinophilia in the
OVA-DC/OVA group was considerably higher than the
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Figure 3
Effect of OVA exposure on lung histology in animals immunized
with DCs. Mice were treated as in Figure 2. At 24 hours after the
last aerosol, lungs were fixed and processed for histological analy-
sis. H&E staining. · 400. (a) Representative section from a mouse
immunized with PBS-DC and exposed to PBS aerosol. No abnor-
malities are noticed. (b and c) Representative sections from mice
immunized with OVA-DC and subsequently exposed to OVA-
aerosol. These mice develop peribronchial and perivascular
eosinophil-rich infiltrates (b) and airway mucosal changes typical
of goblet cell hyperplasia (c).
13.6 ± 1.9% in our initial experiments reported in Fig-
ure 2a. This can be explained by a prolongation of the
OVA-pulsing period, which was initially 2 hours before
adoptive transfer and was subsequently prolonged to
an overnight pulsing in our later experiments (see
Methods). The analysis of BALF of wild-type mice
immunized with OVA-DC obtained from IL4–/– or
IL4+/+ donors revealed a similar degree of airway
eosinophilia in both groups (data not shown).
Role of signaling through T1/ST2. T1/ST2 is a surface
marker known to be differentially expressed on Th2
cells (16, 19, 20). The expression of T1/ST2 on CD4+ T
cells in BALF and in mediastinal and inguinal LNs was
investigated after seven aerosol exposures in OVA-DC
or PBS-DC mice. The frequency of T1/ST2-expressing
CD4+ cells was highest in BALF (62.0 ± 3.8% in OVA-
DC/OVA vs. 8.4 ± 1.5% in PBS-DC/PBS mice (Figure 6a).
This decreased to 13.6% of CD4+ T cells in the medi-
astinal LNs of OVA-DC/OVA mice (versus 3.5% in PBS-
DC/PBS mice). In nondraining inguinal LNs, the
expression of T1/ST2 was the lowest and similar in both
groups (2.9% vs. 2.7% respectively). T1/ST2 was only
weakly expressed on CD3+CD4– T cells (i.e., CD8+ T
cells). We next determined the expression of a putative
ligand for T1/ST2 on DC grown from our bone marrow
cultures. As the ligand for murine T1/ST2 has not been
cloned, no antibodies that directly stain the T1/ST2 lig-
and are available. We have previously cloned the extra-
cellular domain of T1/ST2 into a vector containing the
human IgG1 constant region, generating an expressed
soluble T1/ST2-Ig fusion protein (16). As seen in Figure
6b, DCs bound T1/ST2-Ig weakly but consistently, sug-
gesting the expression of a ligand for T1/ST2.
We investigated the functional contribution of
T1/ST2 to the establishment of eosinophilic airway
inflammation by giving either anti-T1/ST2 mAb
(3E10) or T1/ST2-Ig during the period of intratra-
cheal injection of DCs. Control animals received
either rat IgG or hu-Ig. The intratracheal injection of
either 3E10 (Figure 7a) or T1/ST2-Ig (Figure 7b) at
the time of sensitization by OVA-DC blocked the
development of OVA-induced airway eosinophilia.
Moreover, total numbers of monocytes, neutrophils,
and lymphocytes were significantly reduced. These
changes were also apparent on histological analysis
(data not shown).
Role of costimulation through CD28 on T cells. The develop-
ment of Th2 responses has been shown to depend on
strong costimulation provided by CD80/CD86 on APCs
to CD28 on T cells (21). DCs were purified from CD28+/+
donors and pulsed overnight with 100 m g/mL of OVA. As
expected, immunization with 0.5 · 106 OVA-DC and sub-
sequent exposure to OVA aerosol induced an eosinophilic
response in the airways of CD28+/+ mice (32.2 ± 17.7 · 104
eosinophils/lavage) (Figure 8a). However, this
eosinophilic response was completely suppressed in
CD28–/– mice (1.13 ± 1.1 · 104 eosinophils/lavage). The
absence of eosinophilia in CD28–/– mice was also appar-
ent from histological analysis (data not shown). Despite
these dramatic differences, the number of CD3+ T cells in
BALF was identical between groups (0.6 ± 0.1 · 105 in
CD28+/+ versus 0.4 ± 0.2 · 105 in CD28–/–). The number of
CD4+ cells expressing CD25 and T1/ST2 was, however,
markedly reduced (13.8 ± 1.9% vs. 4.0 ± 1.6% and 14.5 ±
4.6% vs. 2.0 ± 0.4%, respectively) in CD28–/– mice. To deter-
mine the type of Th response induced in the absence of
CD28, we measured cytokine levels after in vitro restim-
ulation with OVA of T cells from draining LNs of OVA-
DC/OVA mice. The levels of IFN-g and IL-4 were signifi-
cantly lower in CD28–/– mice (1,050 ± 67.5 pg/mL and 32
± 3 pg/mL, respectively) compared with CD28+/+ mice
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Table 1
Intracellular staining for cytokines on T cells obtained from BAL
Subset Group CytokinesA
IFN- g IL-4 IFN- g /IL-4 IL-5 IFN- g /IL5
CD4 OVA-DC/OVA 11.9 ± 1.3 17.1 ± 3.4 6.8 ± 1.1 10.4 ± 2.6 3.4 ± 0.6
PBS-DC/PBS 6.7 ± 1.6B 11.9 ± 2.7B 2.1 ± 0.4B – –
CD8 OVA-DC/OVA 27.1 ± 1.4 1.8 ± 0.2 0.9 ± 0.1 0.4 ± 0.1 0.1 ± 0.1
PBS-DC/PBS 14.4 ± 2.8B 2.1 ± 0.4 0.4 ± 0.1 – –
A Cells were obtained from BAL after 7 days of OVA or PBS aerosol and restimulated in vitro for 5 hours using anti-CD3 and anti-CD28 antibodies in the
presence of monensin. Shown is the mean percentage of cells expressing a particular cytokine or combination of cytokines ± SEM from eight mice per group.
BP < 0.05 compared with OVA-DC/OVA group.
Figure 4
Measurement of cytokine levels in unconcentrated BALF and after in
vitro restimulation of LN cells with specific antigen. Mice were treated
as in Figure 2. Groups are coded as immunization/exposure. (a) BALF
was taken 24 hours after the last aerosol exposure and assayed for the
presence of IL-4 and IFN-g by ELISA. IL-5 could not be detected in BALF.
(b and c) Mediastinal and inguinal LNs were resected, and single-cell
suspensions were cultured in vitro for 96 hours in the presence of OVA.
Results represent means ± SEM from five to eight animals per group.
(5,441 ± 1,742 pg/mL and 80 ± 44 pg/mL, respectively.
The levels of IL-5 were lower in CD28–/– (640 ± 60 pg/mL)
than in CD28+/+ mice (877 ± 354 pg/mL), but this did not
reach statistical significance. In contrast, intracellular
staining for cytokines after polyclonal activation with
PMA/ionomycin revealed that individual CD4+ T cells
obtained from BALF of OVA-DC/OVA mice produced
either IFN-g or IL-4 in CD28+/+ mice and that the per-
centage expression of IL-4 in individual cells was not
affected by knockout of the CD28 gene (Figure 8b). How-
ever, the percentage expression of IFN-g in CD28–/– T cells
was almost twice as high compared with CD28+/+ cells.
Discussion
In an attempt to define the role of DCs in the regula-
tion of lung mucosal immunity, we have injected anti-
gen-pulsed myeloid DCs into the trachea of naive
mice. During the afferent phase of the pulmonary
immune response, Ag is deposited into the deeper air-
ways and captured by endogenous APCs, which trans-
port it into the draining LNs (3, 6, 22). In our system,
CFSE-labeled DC could be traced in BALF and drain-
ing mediastinal LNs already 12 hours after injection
into the trachea, but not in nondraining LN or spleen
(data not shown). By 36 hours after injection, labeled
DCs started to disappear from the BAL compartment,
consistent with a further migration into the draining
LNs. In agreement with data from subcutaneous injec-
tion of DCs, the majority of migrated DCs had disap-
peared from the draining LNs by 120 hours after injec-
tion, although significant numbers of cells were
retained in all compartments of the lung studied (23).
Using the same model of adoptive transfer of DCs into
the trachea, we have recently demonstrated that
migrated DCs interact with naive T cells in the medi-
astinal LNs during the so-called central processing
phase of the adaptive pulmonary immune response,
leading to lymphocyte division and generation of
effector cells (6). The time course and distribution of
this primary T-cell response are highly reminiscent of
the kinetics and direction of migration of DCs, as T-
cell division occurs before 48 hours and is restricted to
the mediastinal lymph nodes. This restricted migra-
tion of DCs into the mediastinal LNs of the lung leads
to a compartmentalized immune response (22).
During the effector phase of the immune response,
effector T cells are recruited into the lung and again
stimulated by DCs to release cytokines and orchestrate
airway inflammation (5, 24). The occurrence and the
nature of the secondary effector response reflects the
character of the primary response and the development
of polarized Th1 or Th2 responses during the central
processing phase (25). Challenge with aerosolized OVA
in mice that were immunized by intratracheal injection
of OVA-DC, led to the accumulation of activated CD4+
T lymphocytes in the airways and to eosinophilic airway
inflammation and goblet cell hyperplasia, both charac-
teristic of allergic asthma. As the development of goblet
cell hyperplasia and eosinophilic airway inflammation
is clearly dependent on IL-4 receptor signaling and local
IL-5 production by CD4+ T cells, respectively (26), we
speculated that a Th2-dominated response was induced
by intratracheal injection of DCs. Supporting this
hypothesis, we measured increased levels of Th2 but not
Th1 cytokines in BALF of OVA-DC/OVA mice compared
with PBS-DC/PBS mice. Moreover, when lymphocytes
of the draining mediastinal LNs of OVA-DC/OVA mice
were restimulated with specific Ag, they similarly pro-
duced increased levels of IL4 and IL-5 and identical lev-
els of IFN-g compared with controls. These high levels of
Th2 cytokine production were mainly seen in the LNs
draining the lung, again suggesting the presence of a very
compartmentalized immune response. Intracellular
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Figure 5
Intracellular detection of IFN-g , IL-4, and IL-5 in lymphocytes from
BALF of OVA-DC/OVA mice. As described in Methods, cells were
stained for IFN- g (a and b), IL-4 (a), IL-5 (b), and isotype controls
(c). Dot plots shown were gated on CD3+CD4+ lymphocytes (top) or
CD3+CD8+ lymphocytes (bottom). Number of cells staining for each
cytokine are expressed as a percentage of CD4+ or CD8+ cells. Rep-
resentative of all mice in the group (n = 8).
Figure 6
(a) T1/ST2 expression on BALF cells. Mice were immunized with OVA-
DC and subsequently challenged with OVA as described in Methods.
Control mice (PBS) were immunized with PBS-DC and challenged
with PBS. Single-cell suspensions were surface stained with mAb’s
against CD3, CD4, and T1/ST2. Dot plots were gated on CD3+ viable
lymphocytes. The percentage of CD4+ lymphocytes expressing
T1/ST2+ is indicated. (b) Expression of a putative ligand for T1/ST2
on mouse DCs. Bone marrow DCs were stained for CD11c, MHC
class II, and T1/ST2-Ig, followed by secondary anti–hu-Ig-FITC. As a
control, staining was performed using hu-Ig as primary antibody (bro-
ken line). Histogram was gated on CD11c+ MHC class II+ cells and is
representative of three separate experiments.
staining for cytokines on individual BALF CD3+ T lym-
phocytes revealed that CD4+ lymphocytes were the pre-
dominant cellular source of IL-4 and IL-5. However,
enhanced numbers of CD4+ and CD8+ cells producing
only IFN-g were also clearly detected in BALF. This sug-
gests that eosinophilic inflammation in mice is charac-
terized by an expansion of CD4+ Th2 cells, without selec-
tively abrogating Th1 cells. Similarly, in addition to an
increased number of IL-4– and IL-5–producing cells, a
population of IFN-g –producing CD4+ T cells has been
demonstrated in BALF from asthmatic subjects (27). A
final argument for the induction of a specific Th2
response by DC was the total absence of the eosinophilic
response in mice genetically lacking IL-4. By blocking IL-
4 with antibodies at various time points of the response,
we have previously shown that the absence of IL-4 main-
ly affects the development of Th2 responses during the
central processing phase (i.e., sensitization), whereas the
effector phase is not affected (28, 29).
Despite the high levels of IL-4 measured, we could not
detect significant levels of OVA-specific IgE production
in the serum of OVA-DC/OVA–exposed mice. This is
not surprising, as we immunized the mice by injection
of OVA-pulsed DCs, in the absence of free OVA antigen.
As such, no free antigen was available for stimulation of
naive B cells. Other protocols in which protein-specific
Th2-dependent immunoglobulins were detected after
injection of DCs included the injection of a booster of
soluble protein (11, 30).
Despite the known functional dichotomy of murine Th
responses into Th1- or Th2-cytokine–secreting subsets,
few surface molecules can discriminate between them
(16, 20). The T1/ST2 orphan receptor was found to be
differentially expressed on Th2 clones and on recently dif-
ferentiated Th2 cells in vitro (16, 20). The T1/ST2 belongs
to the IL-1 receptor superfamily and does not bind to any
of its known ligands (31). It was recently demonstrated
that IL-4–, IL-5–, and IL-10–producing CD4+ T cells iso-
lated from granulomas induced by Schistosoma mansoni
eggs express T1/ST2 in vivo (19). Similarly, BALF and
mediastinal CD4+ T cells expressed T1/ST2 in OVA-
DC/OVA animals, whereas T cells from a distant site did
not. This strongly suggested that T1/ST2 expression in
vivo colocalized with the compartmentalized Th2-dom-
inated immune response. In addition to its role as a
marker for Th2 cells, we and others have recently
described that signaling through T1/ST2 is critical for
Th2 development and effector function in vitro and in
vivo (16, 32, 33), although some controversy exists as to
the exact role of T1/ST2 in Th development (34). To
address this further, we analyzed whether DC-induced
Th2 development in the airways was inhibited by block-
ing the interaction of T1/ST2 with its (unknown) ligand.
By injecting blocking antibodies or T1/ST2-Ig fusion pro-
tein at the time of injection of DCs, the sensitization to
inhaled antigen was completely suppressed. This strong-
ly suggested the functional expression of a ligand for
T1/ST2 on DCs, as shown by weak binding of the
T1/ST2-Ig protein. A putative ligand has also been iden-
tified on other APC types such as B cells and follicular
DCs (35). Definite molecular proof of expression on these
cells, as well as studies on its regulation, will await molec-
ular cloning of the ligand for murine T1/ST2.
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Figure 7
Effect of blocking the interaction of T1/ST2 with its ligand during sen-
sitization by OVA-DC on the development of eosinophilic inflamma-
tion. (a) On day 0 of the experiment, mice received an intratracheal
injection of 1 · 106 OVA-DC simultaneously with a rat mAb against
T1/ST2 (3E10) or as a control rat IgG. (b) In another experiment,
mice received an intratracheal injection of 1 · 106 OVA-DC simulta-
neously with a T1/ST2-Ig fusion protein or as a control hu-IgG. Mice
were subsequently exposed to OVA aerosol from day 14 to day 20 and
BALF recovered 24 hours after the last aerosol challenge.
Figure 8
Effect of absence of CD28 on the development of OVA-induced
eosinophilic airway inflammation. On day 0, CD28+/+ and CD28–/–
mice received 5 · 105 OVA-DC from wild-type mice. Mice were sub-
sequently exposed to OVA aerosol from day 14 to day 20 and BALF
was recovered 24 hours after the last aerosol challenge. (a) Differ-
ential cell counting on BALF. Results represent means ± SEM from
six mice per group. (b) Intracellular staining for cytokines on BALF
T cells. Cells were restimulated with PMA/ionomycin in the pres-
ence of monensin and stained for IFN- g and IL-4. Percentage
expression of each cytokine on CD3+CD4+ cells is indicated.
The strong expression of costimulatory molecules
such as CD80 and CD86 is one of the features dis-
criminating lung DCs from other APCs such as B cells
and macrophages (36). It is controversial at present
whether signaling through CD28 by either of these lig-
ands affects the potential of T cells to develop into
either Th1 or Th2 cells (37, 38). It has been suggested
that the induction of Th2 responses in vitro and in
vivo depends on the delivery of a strong costimulus by
the APC to naive T cells (38). We therefore hypothe-
sized that Th2 development and eosinophilia induced
by DC would be absent in mice with a disrupted CD28
gene. Although we found that airway eosinophilia was
completely abrogated, the number of BALF T cells
induced by OVA aerosol was identical between CD28–/–
and wild-type mice. By analogy, recent work in a S.
mansoni–induced model of airway inflammation has
shown that CD28 deficiency abolishes airway
eosinophilia but does not affect the initial recruitment
of T cells into Ag-challenged airways (39). The absence
of airway eosinophilia in CD28–/– mice could be due to
defective Th2 priming or to defective generation of
effector function in Th2 cells during challenge of the
airways. Studies using either CTLA-4Ig or blocking
anti-CD80 and CD86 mAb’s have indeed shown that
costimulation via the CD80/86-CD28 pathway is
essential during both the central processing and the
effector phases of the immune response leading to air-
way eosinophilia (39–41). To clarify this point, lung
effector CD4+ T cells of CD28–/– mice were restimulat-
ed in a costimulation-independent fashion using
PMA/ionomycin and studied for single-cell expression
of cytokines. We found a normal capacity of these cells
to produce IL-4 with an increased tendency to produce
IFN- g , indicating that the priming of Th2 cells by DCs
was unaltered in CD28–/– mice. However, when LN T
cells were restimulated with OVA in a costimulation-
dependent assay, levels of both Th1 and Th2 cytokines
were grossly diminished in CD28–/– mice. We therefore
favor the hypothesis that airway eosinophilia was abol-
ished mainly by a defective activation of effector T cells
in the lung of CD28–/– mice. Consistent with this, we
observed a reduced expression of the activation mark-
er CD25 on CD4+ T cells in CD28–/– mice.
In conclusion, DCs induce Th2-dominated sensitiza-
tion to inhaled Ag, leading to eosinophilic airway
inflammation. These results and our findings that DCs
are essential for the maintenance of airway eosinophil-
ia suggest that these cells are critical to the pathogene-
sis of asthma (5, 24). Therefore, interacting with DC
function is a therapeutic option for this disease.
Acknowledgments
This work was supported by the Concerted
Research Initiative of the University of Ghent
(G.O.A. 98-6) and by the Fund for Scientific
Research Vlaanderen (G.0393.99). We gratefully
acknowledge the technical assistance of G. Barbier,
K. De Saedeleer, M. Gosselin, and S. Lin. The
Inflammation Division of Millenium Pharmaceuti-
cals is supported by Astra Pharmaceuticals.
1. Robinson, D.R., et al. 1992. Predominant Th2-like bronchoalveolar T
lymphocyte population in atopic asthma. N. Engl. J. Med. 326:298–304.
2. Banchereau, J., and Steinman, R.M. 1998. Dendritic cells and the con-
trol of immunity. Nature. 392:245–252.
3. Holt, P.G., Schon-Hegrad, M.A., and Oliver, J. 1988. MHC class II anti-
gen-bearing dendritic cells in pulmonary tissues of the rat (regulation
of antigen presentation activity by endogenous macrophage popula-
tions). J. Exp. Med. 167:262–274.
4. Schon-Hegrad, M.A., Oliver, J., McMenamin, P.G., and Holt, P.G.
1991. Studies on the density, distribution and surface phenotype of
intraepithelial class II major histocompatibility complex antigen
(Ia)–bearing dendritic cells (DC) in the conducting airways. J. Exp.
Med. 173:1345–1356.
5. Lambrecht, B.N., Salomon, B., Klatzmann, D., and Pauwels, R.A. 1998.
Dendritic cells are required for the development of chronic
eosinophilic airway inflammation in response to inhaled antigen in
sensitized mice. J. Immunol. 160:4090–4097.
6. Lambrecht, B.N., Pauwels, R.A., and Fazekas de St.Groth, B. 2000.
Induction of rapid T cell activation, division and recirculation by
intratracheal injection of dendritic cells in a TCR-transgenic model.
J. Immunol. 164:2937–2946.
7. Kalinski, P., Schuitemaker, J.H., Hilkens, C.M., Wierenga, E.A., and
Kapsenberg, M.L. 1999. Final maturation of dendritic cells is associ-
ated with impaired responsiveness to IFN-gamma and to bacterial IL-
12 inducers: decreased ability of mature dendritic cells to produce IL-
12 during the interaction with Th cells. J. Immunol. 162:3231–3236.
8. Maldonado-Lopez, R., et al. 1999. CD8alpha+ and CD8alpha- sub-
classes of dendritic cells direct the development of distinct T helper
cells in vivo. J. Exp. Med. 189:587–592.
9. Rissoan, M.C., et al. 1999. Reciprocal control of T helper cell and den-
dritic cell differentiation. Science. 283:1183–1186.
10. Macatonia, S.E., et al. 1995. Dendritic cells produce IL-12 and direct
the development of Th1 cells from naive CD4(+) T cells. J. Immunol.
154:5071–5079.
11. Stumbles, P.A., et al. 1998. Resting respiratory tract dendritic cells
preferentially stimulate T helper cell type 2 (Th2) responses and
require obligatory cytokine signals for induction of Th1 immunity. J.
Exp. Med. 188:2019–2031.
12. De Becker, G., et al. 1998. Regulation of T helper cell differentiation
in vivo by soluble and membrane proteins provided by antigen-pre-
senting cells. Eur. J. Immunol. 28:3161–3171.
13. De Veerman, M., et al. 1999. Retrovirally transduced bone marrow-
derived dendritic cells require cognate CD4+ T cell help to elicit pro-
tective and therapeutic antitumor immunity. J. Immunol. 162:144–151.
14. Lambrecht, B.N., et al. 1999. Endogenously produced substance P
contributes to lymphocyte proliferation induced by dendritic cells
and direct TCR ligation. Eur. J. Immunol. 29:3815–3825.
15. Ho, W., and Furst, A. 1973. Intratracheal instillation method for
mouse lungs. Oncology. 27:385–393.
16. Lohning, M., et al. 1998. T1/ST2 is preferentially expressed on murine
Th2 cells, independent of interleukin 4, interleukin 5, and interleukin
10, and important for Th2 effector function. Proc. Natl. Acad. Sci. USA.
95:6930–6935.
17. Harding, F.A., McArthur, J.G., Gross, J.A., Raulet, D.H., and Allison,
J.P. 1992. CD28-mediated signalling co-stimulates murine T cells and
prevents induction of anergy in T-cell clones. Nature. 356:607–609.
18. Van Oosterhout, A.J., et al. 1998. Allergen immunotherapy inhibits
airway eosinophilia and hyperresponsiveness associated with
decreased IL-4 production by lymphocytes in a murine model of aller-
gic asthma. Am. J. Respir. Cell Mol. Biol. 19:622–628.
19. Lohning, M., et al. 1999. T1/ST2 expression is enhanced on CD4+ T
cells from schistosome egg–induced granulomas: analysis of Th cell
cytokine coexpression ex vivo. J. Immunol. 162:3882–3889.
20. Xu, D., et al. 1998. Selective expression of a stable cell surface mole-
cule on type 2 but not type 1 helper T cells. J. Exp. Med. 187:787–794.
21. Bluestone, J.A. 1995. New perspectives of CD28-B7–mediated T cell
costimulation. Immunity. 2:555–559.
22. Xia, W.J., Pinto, C.E., and Kradin, R.L. 1995. The antigen-presenting
activities of Ia+ dendritic cells shift dynamically from lung to lymph
node after an airway challenge with soluble antigen. J. Exp. Med.
181:1275–1283.
23. Hermans, I.F., Ritchie, D.S., Yang, J., Roberts, J.M., and Ronchese, F.
2000. CD8+ T cell–dependent elimination of dendritic cells in vivo lim-
its the induction of antitumor immunity. J. Immunol. 164:3095–3101.
24. Lambrecht, B.N., Carro-Muino, I., Vermaelen, K., and Pauwels, R.A.
1999. Allergen-induced changes in bone-marrow progenitor and air-
way dendritic cells in sensitized rats. Am. J. Respir. Cell Mol. Biol.
20:1165–1174.
558 The Journal of Clinical Investigation | August 2000 | Volume 106 | Number 4
25. Lambrecht, B.N., Peleman, R.A., Bullock, G.R., and Pauwels, R.A.
2000. Sensitization to inhaled antigen by intratracheal instillation of
dendritic cells. Clin. Exp. Allergy. 30:214–224.
26. Hogan, S.P., Koskinen, A., Matthaei, K.I., Young, I.G., and Foster, P.S.
1998. Interleukin-5–producing CD4 T cells play a pivotal role in
aeroallergen-induced eosinophilia, bronchial hyperreactivity, and
lung damage in mice. Am. J. Respir. Crit. Care Med. 157:210–218.
27. Krug, N., et al. 1996. T-cell cytokine profile evaluated at the single cell
level in BAL and blood in allergic asthma. Am. J. Respir. Cell Mol. Biol.
14:319–326.
28. Brusselle, G.G., Kips, J.C., Joos, G.F., Bluethmann, H., and Pauwels,
R.A. 1995. Allergen-induced airway inflammation and bronchial
responsiveness in wild-type and interleukin-4-deficient mice. Am. J.
Respir. Cell Mol. Biol. 12:254–259.
29. Coyle, A.J., et al. 1995. Interleukin-4 is required for the induction of
lung Th2 mucosal immunity. Am. J. Respir. Cell Mol. Biol. 13:54–59.
30. Sornasse, T., et al. 1992. Antigen pulsed dendritic cells can efficiently
induce an antibody response in vivo. J. Exp. Med. 175:15–21.
31. Mitcham, J.L., et al. 1996. T1/ST2 signaling establishes it as a mem-
ber of an expanding interleukin-1 receptor family. J. Biol. Chem.
271:5777–5783.
32. Coyle, A.J., et al. 1999. Crucial role of the interleukin 1 receptor fam-
ily member T1/ST2 in T helper cell type 2–mediated lung mucosal
immune responses. J. Exp. Med. 190:895–902.
33. Townsend, M.J., Fallon, P.G., Matthews, D.J., Jolin, H.E., and McKen-
zie, A.N. 2000. T1/ST2-deficient mice demonstrate the importance of
T1/ST2 in developing primary T helper cell type 2 responses. J. Exp.
Med. 191:1069–1076.
34. Hoshino, K., et al. 1999. The absence of interleukin 1 receptor–relat-
ed T1/ST2 does not affect T helper cell type 2 development and its
effector function. J. Exp. Med. 190:1541–1548.
35. Gayle, M.A., et al. 1996. Cloning of a putative ligand for the T1/ST2
receptor. J. Biol. Chem. 271:5784–5789.
36. Masten, B.J., and Lipscomb, M.F. 1999. Comparison of lung dendrit-
ic cells and B cells in stimulating naive antigen-specific T cells. J.
Immunol. 162:1310–1317.
37. Brown, D.R., et al. 1996. Limited role of CD28-mediated signals in T-
helper subset differentiation. J. Exp. Med. 184:803–810.
38. Rulifson, I.C., Sperling, A., Fields, P.E., Fitch, F.W., and Bluestone, J.A.
1997. CD28 costimulation promotes the production of Th2
cytokines. J. Immunol. 158:658–665.
39. Mathur, M., et al. 1999. CD28 interactions with either CD80 or CD86
are sufficient to induce allergic airway inflammation in mice. Am. J.
Respir. Cell Mol. Biol. 21:498–509.
40. Harris, N., et al. 1997. CD80 costimulation is essential for the induc-
tion of airway eosinophilia. J. Exp. Med. 185:177–182.
41. Tsuyuki, S., Tsuyuki, J., Einsle, K., Kopf, M., and Coyle, A.J. 1997. Cos-
timulation through B7-2 (CD86) is required for the induction of a
lung mucosal T helper cell 2 (TH2) immune response and altered air-
way responsiveness. J. Exp. Med. 185:1671–1679.
The Journal of Clinical Investigation | August 2000 | Volume 106 | Number 4 559
